1
|
Lobaina Y, Urquiza D, Garay H, Perera Y, Yang K. Evaluation of Cell-Penetrating Peptides as Mucosal Immune Enhancers for Nasal Vaccination. Int J Pept Res Ther 2021; 27:2873-2882. [PMID: 34658688 PMCID: PMC8511864 DOI: 10.1007/s10989-021-10296-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/29/2021] [Indexed: 11/09/2022]
Abstract
Cell-penetrating peptides (CPPs) have been evaluated as enhancers in drug delivery, their addition in medical formulations favors drug absorption allowing obtaining the pharmacological effect with lower doses. In vaccine formulations their inclusion has been also explored with interesting results. Currently mucosal vaccination constitutes a promising alternative with the main advantage of inducing both systemic and mucosal immune responses, which are crucial for control tumors and infections at mucosal tissues. In the present work the nasal immune-enhancing effect of four CPPs was evaluated in Balb/c mice. Animals were intranasally immunized with CPP and the recombinant hepatitis B surface protein (HBsAg) as model antigen. The antibody response in sera and mucosal tissue was measured by ELISA. The IFN-γ secretion response at spleen was also evaluated by ELISPOT and ELISA. Among the CPPs studied one novel peptide stand out by its ability to potentiate the humoral and cellular immune response against the co-administered antigen. Considering that the use of mucosal routes is a promising strategy in vaccination, which are gaining special relevance nowadays in the development of novel candidates against SARS-CoV-2 and other potential emerging respiratory virus, the searching and development of safe mucosal adjuvants constitute a current need.
Collapse
Affiliation(s)
- Yadira Lobaina
- Biomedical Research Division, Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), 10600 Havana, Cuba.,China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Yongzhou Zhong Gu Biotechnology Co., Ltd, Lengshuitan District, Yongzhou City, 425000 Hunan Province China
| | - Dioslaida Urquiza
- Animal Facilities, Center for Genetic Engineering and Biotechnology, 10600 Havana, Cuba
| | - Hilda Garay
- Biomedical Research Division, Peptide Synthesis Lab, Center for Genetic Engineering and Biotechnology, 10600 Havana, Cuba
| | - Yasser Perera
- Biomedical Research Division, Pharmaceutical Department, Molecular Oncology Group, Center for Genetic Engineering and Biotechnology, 10600 Havana, Cuba.,China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Yongzhou Zhong Gu Biotechnology Co., Ltd, Lengshuitan District, Yongzhou City, 425000 Hunan Province China
| | - Ke Yang
- China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Yongzhou Zhong Gu Biotechnology Co., Ltd, Lengshuitan District, Yongzhou City, 425000 Hunan Province China
| |
Collapse
|
2
|
Granadillo M, Batte A, Alfonso AB, Blanco A, Urquiza D, Varas L, Soler D, Miyares M, Limonta M, Torrens I. Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate. Vaccine 2019; 37:3957-3960. [PMID: 31155419 DOI: 10.1016/j.vaccine.2019.05.060] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2018] [Revised: 05/14/2019] [Accepted: 05/21/2019] [Indexed: 12/24/2022]
Abstract
Cervical cancer is a global public health problem and human papillomavirus (HPV) 16 accounts for approximately 50% of cases worldwide. Although there are several types of HPV therapeutic vaccines in clinical research, there are currently not approved for use in humans. We developed the fusion protein LALF32-51-E7 (hereafter denominated CIGB550-E7) defined by a cell-penetrating peptide linked to an E7 mutein for the treatment of HPV16-associated tumors. We have demonstrated previously the benefit on antitumor response induced by the immunization with CIGB550-E7 admixed with very small size proteoliposomes (VSSP) adjuvant compared with the adjuvant-free immunization. In this study, we obtained a similar antitumor response in mice immunized with CIGB550-E7 admixed with the new adjuvant sVSSP that does not contain any animal-derived product. Also, the immunization with the above mentioned vaccine preparation induced a cell-mediated immune response. Our results are encouraging for the future clinical trials with the vaccine candidate CIGB550-E7+sVSSP.
Collapse
Affiliation(s)
- Milaid Granadillo
- Pharmaceutical Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba.
| | - Aileen Batte
- Pharmaceutical Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Alain B Alfonso
- Pharmaceutical Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Aracelys Blanco
- Direction of Preclinical Investigations and Animal Experimentation, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Dioslaida Urquiza
- Direction of Preclinical Investigations and Animal Experimentation, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Laura Varas
- Direction of Technological Development. Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Dayana Soler
- Direction of Technological Development. Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Maelys Miyares
- Direction of Technological Development. Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Miladys Limonta
- Direction of Technological Development. Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Isis Torrens
- Pharmaceutical Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| |
Collapse
|
3
|
Assessment of in vivo anti-tumor activity of human umbilical vein endothelial cell vaccines prepared by various antigen forms. Eur J Pharm Sci 2017; 114:228-237. [PMID: 29277666 DOI: 10.1016/j.ejps.2017.12.020] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2017] [Revised: 12/20/2017] [Accepted: 12/21/2017] [Indexed: 01/07/2023]
Abstract
Human umbilical vein endothelial cell (HUVEC) vaccine has been proved as an effective whole-cell vaccine, but the modest therapeutic anti-tumor efficiency limits its clinical use. Various antigen forms, including paraformaldehyde-fixed HUVEC, glutaraldehyde-fixed HUVEC, HUVEC lysate and live HUVEC, have been intensively used in HUVEC vaccine preparation, however, the most effective antigen form has not yet been identified. In the present study, these four commonly used antigen forms were used to prepare vaccines named Para-Fixed-EC, Glu-Fixed-EC, Lysate-EC, and Live-EC respectively, and the anti-tumor efficacy of these four vaccines was investigated. Results showed that Live-EC exhibited the most favorable anti-tumor growth and metastasis effects among the four vaccines in both H22 hepatocellular carcinoma and Lewis lung cancer models. High titer anti-HUVEC antibodies were detected in Live-EC immunized mice sera, and the immune sera of Live-EC group could significantly inhibit HUVEC proliferation and tube formation. Moreover, T cells isolated from Live-EC immunized mice exhibited strong cytotoxicity against HUVEC cells, with an increasing IFN-γ and decreasing Treg production in Live-EC immunized mice. Finally, CD31 immunohistochemical analysis of the excised tumors verified a significant reduction in vessel density after Live-EC vaccination, which was in accordance with the anti-tumor efficiency. Taken together, all the results proved that live HUVEC was the most effective antigen form to induce robust HUVEC specific antibody and CTL responses, which could lead to the significant inhibition of tumor growth and metastasis. We hope the present findings would provide a rationale for the further optimization of HUVEC vaccine.
Collapse
|